Rett syndrome (RTT) is a severe X-linked neurodevelopmental disorder that primarily affects females, occurring in approximately 1 in 10,000 to 15,000 live female births worldwide. It is caused predominantly by loss-of-function mutations in the MECP2 gene (methyl-CpG-binding protein 2) located on the X chromosome (Xq28). Rett syndrome is characterized by apparently normal early development followed by a period of developmental regression, with loss of acquired purposeful hand skills and spoken language, onset of stereotypic hand movements, and gait abnormalities. [@samarasinghe2021]
Although Rett syndrome is classified as a neurodevelopmental disorder rather than a classical neurodegenerative disease, it shares several features with [neurodegeneration](/diseases/neurodegeneration) including progressive neurological regression, [synaptic dysfunction](/mechanisms/synaptic-failure), [neuroinflammation](/mechanisms/neuroinflammation), [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction), and oxidative stress. The study of Rett syndrome has provided critical insights into the role of epigenetic regulation in brain function and has become a model for understanding how disruption of chromatin-based gene regulation leads to neurological disease. [@percy1995]
In 2023, trofinetide (Daybue) became the first FDA-approved treatment specifically for Rett syndrome, marking a major milestone for this condition. [@sadhu2023]
Rett syndrome (RTT) is a severe X-linked neurodevelopmental disorder that primarily affects females, occurring in approximately 1 in 10,000 to 15,000 live female births worldwide. It is caused predominantly by loss-of-function mutations in the MECP2 gene (methyl-CpG-binding protein 2) located on the X chromosome (Xq28). Rett syndrome is characterized by apparently normal early development followed by a period of developmental regression, with loss of acquired purposeful hand skills and spoken language, onset of stereotypic hand movements, and gait abnormalities. [@samarasinghe2021]
Although Rett syndrome is classified as a neurodevelopmental disorder rather than a classical neurodegenerative disease, it shares several features with [neurodegeneration](/diseases/neurodegeneration) including progressive neurological regression, [synaptic dysfunction](/mechanisms/synaptic-failure), [neuroinflammation](/mechanisms/neuroinflammation), [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction), and oxidative stress. The study of Rett syndrome has provided critical insights into the role of epigenetic regulation in brain function and has become a model for understanding how disruption of chromatin-based gene regulation leads to neurological disease. [@percy1995]
In 2023, trofinetide (Daybue) became the first FDA-approved treatment specifically for Rett syndrome, marking a major milestone for this condition. [@sadhu2023]
The MECP2 gene encodes methyl-CpG-binding protein 2, a nuclear protein that binds to methylated DNA and modulates gene expression. MeCP2 is particularly abundant in mature neurons, where it is expressed at levels comparable to histones (approximately 16 million molecules per neuronal nucleus). MeCP2 functions as both a transcriptional activator and repressor, acting as a global regulator of chromatin architecture. Through its methyl-CpG binding domain (MBD) and transcription repression domain (TRD), MeCP2 recruits corepressor complexes (NCoR/SMRT, Sin3A), histone deacetylases (HDACs), and other chromatin-modifying factors to methylated genomic regions. [@guy2007]
MeCP2 has two major isoforms: MeCP2-e1 (encoded by exons 1, 3, and 4) and MeCP2-e2 (encoded by exons 2, 3, and 4). The MeCP2-e1 isoform is the predominant form in the brain and is the one most commonly affected in Rett syndrome. [@lampl2019] Over 900 different pathogenic mutations have been identified in MECP2, including missense mutations, nonsense mutations, frameshift mutations, and large deletions. Eight recurrent missense and nonsense mutations account for approximately 70% of all cases: R106W, R133C, T158M, R168X, R255X, R270X, R294X, and R306C. [@liyanage2014]
Rett syndrome follows X-linked dominant inheritance. Because the MECP2 gene is on the X chromosome, affected females are heterozygous for the mutation. Due to random X-chromosome inactivation (XCI), each cell expresses either the wild-type or mutant allele, creating a mosaic pattern of MeCP2 expression. The ratio of cells expressing wild-type vs. mutant MeCP2 significantly influences disease severity. Favorable skewing (more cells expressing wild-type) correlates with milder phenotypes. [@rao1987]
Males with MECP2 mutations typically present with severe neonatal encephalopathy and often do not survive beyond early childhood, unless they have Klinefelter syndrome (47,XXY), somatic mosaicism, or hypomorphic mutations that allow some residual MeCP2 function. [@liu2025]
While classic Rett syndrome is caused by MECP2 mutations, atypical variants have been associated with mutations in other genes:
Rett syndrome follows a characteristic four-stage progression:
Stage I - Early Onset (6-18 months): Development appears normal or shows subtle delays. Early signs may include hypotonia, diminished eye contact, and reduced interest in toys. Hand wringing or mouthing may begin. This stage is often missed or attributed to normal variation.
Stage II - Rapid Regression (1-4 years): This dramatic stage involves loss of previously acquired hand skills and spoken language, onset of characteristic hand stereotypies (wringing, washing, clapping, tapping, squeezing), development of breathing irregularities, social withdrawal resembling autism, and onset of seizures in some cases. Deceleration of head growth becomes apparent.
Stage III - Plateau (2-10+ years): After the regression period, some stability occurs. Social engagement and communication may partially improve. Seizures may become more prominent. Motor deterioration progresses with development of spasticity, dystonia, and [scoliosis](/mechanisms/scoliosis). Some individuals remain in this stage for decades.
Stage IV - Late Motor Deterioration (10+ years): Progressive loss of mobility with increased rigidity and spasticity. Many individuals become wheelchair-dependent. Scoliosis worsens. Cognitive abilities generally stabilize. Seizures may decrease in frequency.
Neurological manifestations:
The Rett syndrome brain shows characteristic volumetric reductions without frank neurodegeneration or neuronal death. Overall brain volume is reduced by 12-34%, with the most pronounced reductions in the [putamen](/brain-regions/putamen), [hippocampus](/brain-regions/hippocampus), [corpus callosum](/brain-regions/corpus-callosum), and [caudate nucleus](/brain-regions/caudate-nucleus). Neuronal cell bodies are smaller and more densely packed, particularly in layers III and V of the cerebral [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), [basal ganglia](/brain-regions/basal-ganglia), and [substantia nigra](/brain-regions/substantia-nigra).
The most striking neuropathological finding is reduced dendritic complexity and spine density, suggesting that MeCP2 is critical for synaptic maturation and maintenance rather than neuronal survival. Dendritic arborization is reduced in cortical pyramidal neurons, and spine density is decreased across multiple brain regions. These findings support the concept that Rett syndrome is primarily a disorder of synaptic maturation and connectivity rather than neuronal degeneration.
Rett syndrome involves widespread neurotransmitter dysregulation:
[Astrocytes](/cell-types/astrocytes) dysfunction contributes significantly to Rett syndrome pathophysiology. MeCP2-deficient astrocytes fail to properly support neuronal growth and synaptic function, and transplantation of wild-type astrocytes or restoration of MeCP2 expression in astrocytes partially rescues neuronal deficits in mouse models. [Microglia](/cell-types/microglia) also play a role in disease progression through neuroinflammatory mechanisms. [@kyle2018]
MeCP2 loss disrupts the epigenome on a global scale. Genome-wide studies have revealed widespread alterations in DNA-methylation patterns, histone modifications, and chromatin accessibility in MeCP2-deficient neurons. Notably, MeCP2 binds to methylated CpG dinucleotides and also to methylated CpA (mCA) sites, which are abundant in the brain. Loss of MeCP2 leads to de-repression of long genes (>100 kb) that are enriched in mCA sites, causing subtle but widespread changes in gene expression that collectively disrupt neuronal function.
[Mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction) is a consistent finding in Rett syndrome. MeCP2-deficient cells show altered mitochondrial morphology, reduced respiratory chain complex activity, increased oxidative stress, and impaired energy metabolism. The mitochondrial abnormalities may contribute to the multisystem nature of Rett syndrome, affecting not only the brain but also skeletal muscle, bone, and cardiac tissue.
The prevailing model suggests that MeCP2 is not required for neuronal development or migration but is essential for the later stages of neuronal maturation - including synaptogenesis, dendritic growth, and activity-dependent circuit refinement. Without MeCP2, neurons fail to fully mature and maintain their synaptic connections. Critically, restoration of MeCP2 expression in mature MeCP2-null mice can reverse many neurological deficits, demonstrating that the condition is not irreversible. [@guy2007]
Trofinetide, approved by the FDA in March 2023, is a synthetic analog of the N-terminal tripeptide of insulin-like growth factor 1 (IGF-1), glycine-proline-glutamate (GPE). It is the first and only treatment approved specifically for Rett syndrome. In the pivotal LAVENDER phase 3 trial, trofinetide demonstrated statistically significant improvements in the Rett Syndrome Behaviour Questionnaire (RSBQ) and the Clinical Global Impression-Improvement (CGI-I) scale compared to placebo. [@sadhu2023]
Long-term safety and efficacy data from the LILAC-2 open-label extension study showed sustained improvements and an acceptable safety profile, with the most common adverse events being diarrhea and vomiting.
Gene therapy represents a potentially transformative approach for Rett syndrome:
Rett syndrome occurs in all ethnic and racial groups worldwide with an estimated prevalence of approximately 1 in 10,000 to 15,000 females. The vast majority of cases (>95%) arise from de novo mutations, and most originate on the paternal X chromosome. The incidence in males is extremely rare due to the hemizygous state being largely lethal in utero or in early infancy.
Current research priorities include: